Abstract
A 64-year-old woman was admitted to our hospital for recurrent stroke and cognitive impairment and was diagnosed with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Iodine-123 iodoamphetamine single photon emission computed tomography showed hypoperfusion in the whole brain, but cerebral blood flow increased dramatically after the administration of acetazolamide in the cerebral cortex. Lomerizine, a diphenylmethylpiperazine Ca2+ channel blocker, can selectively increase cerebral blood flow. Cognitive decline and cerebral hypoperfusion improved during 2-year administration of lomerizine in this CADASIL patient, and thus, lomerizine is a potential candidate for treating cognitive impairment in CADASIL patients.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amphetamine
-
CADASIL / complications*
-
CADASIL / drug therapy
-
Calcium Channel Blockers / administration & dosage
-
Calcium Channel Blockers / pharmacology
-
Calcium Channel Blockers / therapeutic use*
-
Cerebral Cortex / diagnostic imaging
-
Cerebral Cortex / drug effects
-
Cerebral Cortex / physiopathology*
-
Cognition Disorders / drug therapy*
-
Cognition Disorders / etiology
-
Diffusion Magnetic Resonance Imaging / methods
-
Dopamine Uptake Inhibitors
-
Female
-
Humans
-
Iodine Isotopes
-
Middle Aged
-
Piperazines / administration & dosage
-
Piperazines / pharmacology
-
Piperazines / therapeutic use*
-
Tomography, Emission-Computed / methods
-
Tomography, Emission-Computed, Single-Photon / methods
Substances
-
Calcium Channel Blockers
-
Dopamine Uptake Inhibitors
-
Iodine Isotopes
-
Piperazines
-
Amphetamine
-
lomerizine